Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer

2018 ◽  
Vol 378 (2) ◽  
pp. 192-193 ◽  
Author(s):  
Sanjay Popat
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutated ◽  
First Line Treatment

Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer

2019 ◽  
Vol 15 (2) ◽  
pp. 181-191
Author(s):  
Hao Wang ◽  
Chenxin Zeng ◽  
Xin Li ◽  
Youjie Wang ◽  
Xinyi Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cost Utility ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutated ◽  
First Line Treatment

Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer

2019 ◽  
Vol 12 (9) ◽  
pp. 831-840 ◽  
Author(s):  
Mariacarmela Santarpia ◽  
Jessica Menis ◽  
Imane Chaib ◽  
Maria Gonzalez Cao ◽  
Rafael Rosell
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutated ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document